OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EVEX55

Evexia Lifecare Ltd

Commodity ChemicalsVerified

Evexia Lifecare Ltd has a debt-to-equity ratio of 0.81 and a current ratio of 1.66, indicating moderate leverage and acceptable short-term liquidity. However, the company's operating cash flow is negative at -44.14 million INR, and free cash flow is only 8.84 million INR, suggesting limited cash generation capacity. The company's profitability is weak, with a return on equity of 0.09% and a return on assets of 0.05%, both significantly below the typical performance metrics for the Commodity Chemicals industry. The operating income is negative at -14.28 million INR, highlighting operational inefficiencies. Evexia Lifecare Ltd operates in a single segment, the Trading of Chemical products, and does not disclose geographic revenue concentration. This lack of diversification increases exposure to sector-specific risks. The company's growth trajectory is unclear, as no specific revenue growth rates or future projections are provided in the available data. The negative operating income and low profitability suggest challenges in sustaining growth. The risk assessment indicates medium liquidity risk and low dilution risk. However, the company has negative net cash after subtracting total debt, which could constrain its ability to fund operations or invest in growth. No recent events, such as filings or transcripts, are provided in the input data to inform the company's current strategic or operational developments.

30-day price · EVEX+0.75 (+147.1%)
Low$0.47High$1.28Close$1.26As of15 May, 00:00 UTC
Profile
CompanyEvexia Lifecare Ltd
TickerEVEX.BO
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Evexia Lifecare Ltd is engaged in the trading of chemicals, agriculture produce, and consumer goods, primarily operating in the Trading of Chemical products segment.

Classification. Evexia Lifecare Ltd is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with a confidence level of 0.92.

Evexia Lifecare Ltd has a debt-to-equity ratio of 0.81 and a current ratio of 1.66, indicating moderate leverage and acceptable short-term liquidity. However, the company's operating cash flow is negative at -44.14 million INR, and free cash flow is only 8.84 million INR, suggesting limited cash generation capacity. The company's profitability is weak, with a return on equity of 0.09% and a return on assets of 0.05%, both significantly below the typical performance metrics for the Commodity Chemicals industry. The operating income is negative at -14.28 million INR, highlighting operational inefficiencies. Evexia Lifecare Ltd operates in a single segment, the Trading of Chemical products, and does not disclose geographic revenue concentration. This lack of diversification increases exposure to sector-specific risks. The company's growth trajectory is unclear, as no specific revenue growth rates or future projections are provided in the available data. The negative operating income and low profitability suggest challenges in sustaining growth. The risk assessment indicates medium liquidity risk and low dilution risk. However, the company has negative net cash after subtracting total debt, which could constrain its ability to fund operations or invest in growth. No recent events, such as filings or transcripts, are provided in the input data to inform the company's current strategic or operational developments.
Key takeaways
  • Evexia Lifecare Ltd has a moderate debt-to-equity ratio but faces liquidity challenges due to negative operating cash flow.
  • The company's profitability is weak, with return on equity and return on assets well below industry norms.
  • The company operates in a single segment, increasing its exposure to sector-specific risks.
  • Growth prospects are uncertain, with no clear revenue growth indicators provided in the data.
  • The company has low dilution risk but faces liquidity constraints due to negative net cash.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$838.9M
Gross profit$11.4M
Operating income-$14.3M
Net income$4.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$44.1M
CapEx
Free cash flow$8.8M
Total assets$8.94B
Total liabilities$4.35B
Total equity$4.60B
Cash & equivalents
Long-term debt$3.75B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$4.60B
Net cash-$3.75B
Current ratio1.7
Debt/Equity0.8
ROA0.1%
ROE0.1%
Cash conversion-10.7%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
MetricEVEXActivity
Op margin-1.7%0.4% medp25 -8.0% · p75 16.0%below median
Net margin0.5%2.3% medp25 -11.6% · p75 11.8%below median
Gross margin1.4%20.8% medp25 14.9% · p75 24.0%bottom quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue6.2% medp25 5.4% · p75 10.2%
Debt / equity81.0%59.0% medp25 54.9% · p75 72.9%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 21:03 UTC#c766adbe
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 21:04 UTCJob: 63f3330c